Latest filing published 29 Jan 2016 for Agile Therapeutics INC, €2.3M.
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
Jay Moorin: trading record in brief
Jay Moorin discloses dealings in 6 companies, chiefly Avanir Pharmaceuticals, Eagle Pharmaceuticals, Inc. and Agile Therapeutics Inc. The record holds 53 filings, for trades running from 12 April 2006 to 27 January 2016.
In open-market terms, that means 29 purchases worth €20.7M on one side and 6 sales worth €6.4M on the other. Netting one side against the other leaves €14.3M of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Other entries cover 3 share grants. In 2016 alone, the filings show 1 purchase and no sales.
A typical purchase (the median) is worth €60k.
The newest entry dates from 29 January 2016: an open-market purchase of €2.3M, in Agile Therapeutics Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Jay Moorin
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 393,700 shares@ US$6.35100.0% of flowCommon StockSEC:0000932440-16-000309:0Canonical exit: 26 Apr 2016 (T+90)
- 811,966 shares@ US$5.85Common StockSEC:0000932440-15-000034:0Canonical exit: 23 Apr 2015 (T+90)
- 164,417 sharesCommon StockSEC:0000932440-14-000212:0
- 1,950,200 sharesCommon StockSEC:0000932440-14-000212:1
- 460,350 sharesCommon StockSEC:0000932440-14-000212:2
- 158,174 shares@ US$6.00Common StockSEC:0000932440-14-000212:3
- 1,120,833 shares@ US$6.00Common StockSEC:0000932440-14-000212:4Canonical exit: 27 Aug 2014 (T+90)
- 62,575 sharesCommon Stock, $0.001 par valueSEC:0001209191-14-012764:6
- 9,359 sharesCommon Stock, $0.001 par valueSEC:0001209191-14-012764:7
- 357 sharesCommon Stock, $0.001 par valueSEC:0001209191-14-012764:8
- 1,927,986 sharesCommon Stock, $0.001 par valueSEC:0001209191-14-012764:0
- 1,028,613 sharesCommon Stock, $0.001 par valueSEC:0001209191-14-012764:1
- 850,520 sharesCommon Stock, $0.001 par valueSEC:0001209191-14-012764:2
- 569,538 sharesCommon Stock, $0.001 par valueSEC:0001209191-14-012764:3
- 21,837 sharesCommon Stock, $0.001 par valueSEC:0001209191-14-012764:4
- 333,333 shares@ US$15.00Common Stock, $0.001 par valueSEC:0001209191-14-012764:5Canonical exit: 19 May 2014 (T+90)
- 297,571 shares@ US$1.888Common StockSEC:0000932440-10-000272:0
- 4,848,485 shares@ US$0.165Common StockSEC:0000932440-10-000071:0Canonical exit: 29 Jun 2010 (T+90)
- 23,237,083 shares@ US$0.1574Common StockSEC:0000932440-10-000006:0
- 493,452 shares@ US$3.5208Common StockSEC:0000932440-09-000720:0
- 70,000 shares@ US$3.2443Common StockSEC:0000932440-09-000720:1
- 804,712 shares@ US$2.46Class A Common StockSEC:0000932440-09-000687:0
- 427,145 shares@ US$2.12Class A Common StockSEC:0000932440-09-000687:1
- 547,135 shares@ US$2.23Class A Common StockSEC:0000932440-09-000687:2
- 894,120 shares@ US$3.58Class A Common StockSEC:0000932440-09-000633:0
25 of 53 declarations
